Valvular & structural heart diseaseCohort study
Early outcomes of redo-TAVI with the SAPIEN 3 platform: the prospective, multicentre ReTAVI registry
- prospective, international study
- registry
- consecutive patients
- 59 international centres
- imaging centrally analysed
- major clinical events adjudicated by an independent committee
Authors' conclusion
Redo-TAVI with a balloon-expandable SAPIEN 3 THV platform is a safe and effective reintervention strategy across diverse failed THV types, when guided by the Heart Team, standardised procedural planning, and comprehensive imaging.
Study context
- Population
- Patients with a failed aortic transcatheter heart valve (THV) undergoing redo-TAVI with a balloon-expandable SAPIEN 3 THVenrolled
- Participants
- 143 patients
Main finding
As reported in the abstract
Baseline characteristics
median age
84 years
female
40.6%
median Society of Thoracic Surgeons risk score
7.0%
Observational data: associations, not effects.
Further findings
Failing THV platform
- balloon-expandable SAPIEN 3
- 30.1%
- self-expanding CoreValve/Evolut
- 53.1%
- ACURATE
- 14.0%
Failure mode
- isolated regurgitation
- 48.6%
- stenosis
- 35.2%
- mixed pathology
- 16.2%
Replacement valve successfully implanted
- successful implantation
- 95.1%
Mortality · 30 days
- 30-day mortality rate
- 3.5%
Mean gradient change
- overall
- Δ=−12.0 mmHg
- stenotic failures
- Δ=−29.0 mmHg
Safety
Stroke and pacemaker implantation · 30 days
- stroke
- 0.7%
- pacemaker implantation
- 6.3%
Coronary obstruction
- coronary obstruction
- 1.4%
Original publication
Early outcomes of redo-TAVI with the SAPIEN 3 platform: the prospective, multicentre ReTAVI registry. EuroIntervention. Published 1 June 2026. doi:10.4244/eij-d-25-01268
Summarised from the published abstract; every number is checked against it